In our study [1] , we used the monoclonal antibody to cytokeratins 8/18 from Leica Microsystems, which is derived from the 5D3 clone and reacts with human cytokeratin-intermediate filament proteins 8 and 18 at 52 and 45 kD respectively [2] . The above clone is highly specific for identification of gastric and colorectal adenocarcinomas [3] .
In the Immunohistochemistry section of the Patients and Materials, we annotated the cytokeratin 8/18 within the parentheses (CAM5.2, clone 5D3, Novocastra) based on the information presented on the section for cytokeratin 8/18, clone 5D3 on the IHC and ISH 2007-2009 product range catalogs of Vision Biosystems/Leica Microsystems, in which the above clone shares similar specificities to clone CAM5.2 according to research data presented by Angus et al. [4] , as well as the mentions in several reference pathology books and review papers, to be the preferred antibody clone for the detection of cytokeratins 8/18 in tumors [5] [6] [7] . These views appeared to be based on the initial report of Makin et al. [8] , which identified the reactive cytokeratins of clone CAM5.2 as having molecular weights of 39, 43, and 50 kD, corresponding to cytokeratins 19, 18, and 8 respectively of Moll's catalog. Subsequently, Smedts et al. [9] presented data that clone Cam 5.2 shows specific reactivity for cytokeratin 8 and is less reactive for the closely related cytokeratin 7 and unrelated to 18 or 19.
It is clear that a controversy exists as to the cytokeratins recognized by Cam 5.2 even in recent publications [10, 11] , in which is cited as ''8/18/CAM5.2''. It seems that the Cam 5.2 antibody in pathology community erroneously is still synonymous to cytokeratins 8/18.
